Summary Although women with breast cancer tend to have a greater proportion of their circulating oestradiol non-protein bound and albumin bound, and less SHBG-bound, than controls, it remains uncertain whether this has an aetiological role or is an effect of the tumour. Oestradiol and its binding to serum proteins was investigated: (a) in relation to risk factors for breast cancer in a normal population; (b) 
For long it has been believed that many forms of breast disease, particularly breast cancer, have a hormonal origin. In particular, because of its profound stimulatory influence on breast ductal epithelium, it was thought that oestradiol must play a central role. Differences in the total concentration of oestradiol, however, are generally not apparent between patients with breast cancer and normal controls, particularly for premenopausal women (Moor et al., 1982; Reed et al., 1983; Ota et al., 1986) . In recent years the concept of bioavailability of oestradiol has been recognised, oestradiol being mostly loosely bound to albumin, about one-third tightly bound to sex hormone binding globulin (SHBG) and a few per cent non-protein bound or 'free' . It is the free and albumin bound components which are available to the tissues and are therefore the functionally important proportion of oestradiol. A number of studies have demonstrated that the proportions of free and albumin bound oestradiol are higher in breast cancer patients (Moore et al., 1982; Reed et al., 1983; Ota et al., 1986) .
Postulating an aetiological role is difficult as the changes in binding may be an effect of the disease rather than cause. To try to provide further evidence we have investigated associations between known risk factors and oestradiol binding in a study population consisting of breast cancer patients, patients with histologically categorised benign breast disease and 'normal' community controls. The benign breast disease patients were grouped into those who histologically had evidence of epithelial hyperplasia and hence had an increased risk of subsequently developing breast cancer, and those with only changes of fibrosis and cystic disease who should not have had any increase in risk (Page et al., 1978 (Willcox et al., 1983) Associations between risk factors for breast cancer and each of the hormonal variables were determined by one-way analysis of variance after categorising the risk factor into relevant sub-groups (F test) , utilising one-sided P values. In addition, associations between risk factors and the hormonal variables were tested by linear regression analysis and after adjusting for Quetelet's index. Analyses were repeated after logarithmic transformation of the hormonal variable. These associations were determined using only the control population.
Women taking the oral contraceptive pill (25), oestrogen replacement therapy (19) , tamoxifen (15) or undergoing cytotoxic therapy (1) were excluded from analyses. In addition, the group of premenopausal women who had had a hysterectomy were excluded from analyses involving total concentration of oestradiol or progesterone as their stage of the menstrual cycle could not be determined (66) .
Results

Patients and controls
One hundred and eight patients with invasive breast cancer, 96 patients with benign epithelial hyperplasia of the breast and 96 patients with fibrocystic disease of the breast but without epithelial hyperplasia were studied. The patients with epithelial hyperplasia and fibrocystic disease shared a common control subject, and in total 214 community control subjects were studied. Seventy-eight per cent of contactable control subjects agreed to take part in the study while 84% of contacted patients took part.
Age
Both variables of bioavailability of oestradiol, i.e. the free and albumin bound components, showed the same pattern of being high in the young age group and progressively falling, reaching a low in the perimenopausal years, thereafter rising as age increased. This pattern was supported by the changes in SHBG concentration which were diametrically opposite, reaching a peak in the perimenopausal years ( Figure 1 and Table I ). Adjusting for QI improved the statistical significance for these associations (free oestradiol P = 0.0156, albumin-bound oestradiol P = 0.0116, SHBG P = 0.5297).
Country of birth There were few Europe-born and Asia-born women. There was little difference between the other countries of birth for any of the hormonal variables. This applied even after reanalysis for those who had been in Australia for less than 15 years (Table I ).
Age at menarche The recalled age at menarche was plotted for each of the hormonal variables (Figure 2 ). The only pattern to emerge Albumin bound Free oestradiol (%) oestradiol (%) Age Figure 1 The proportion of free and albumin bound oestradiol, and concentration of SHBG plotted by age in 10-year age groups for normal population, showing a fall in oestradiol binding and a rise in SHBG in the perimenopausal years. These changes appear to be independant of body mass changes. (Mean ± s.e.m.) was a stepwise fall in SHBG concentration for decreasing recalled age at menarche. This was not statistically significant (Table I) . Similarly, when analysed by linear regression there were no significant associations with the hormonal variables.
Age at menopause
The recalled age at menopause was plotted for each of the hormonal variables (Figure 2 ). For both the total concentration of oestradiol and the proportion of oestradiol which was bioavailable (free and albumin bound) there was a progressive stepwise increase with increasing age at menopause. Similarly, for the concentration of SHBG there was a reduction in SHBG with increasing age at menopause (Table I) . After adjusting for QI, however, these patterns largely disappeared, as did any trend to statistical significance (free oestradiol P = 0.8943, albumin bound oestradiol P = 0.8458, SHBG P = 0.8058). Linear regression analysis was not significant for any of the hormonal variables. (Figure 3 ). For post-menopausal women there was a progressive rise in total oestradiol with increasing obesity, but this did not apply for premenopausal women (Table I) . Linear regression analysis confirmed these associations.
Parity
There were no associations apparent between the variables of oestradiol binding and the number of full term pregnancies.
Age at first pregnancy As with parity there were no associations between oestradiol binding and the age at first pregnancy although again there did appear to be an association with the total concentration of oestradiol for post-menopausal women. Post-menopausal women who had a late age at first pregnancy had a higher concentration of total oestradiol but this again was not significant (Table I) .
Family history There did not appear to be any association between family history of breast cancer and oestradiol binding although women who had a first degree relative who had had breast cancer had a rather lower SHBG concentration. This was not statistically significant. The number of women in the study group with a family history of breast cancer was relatively small and when divided into sub-groups, e.g. pre and postmenopausal or multiple relatives, the numbers were too small to be meaningful (Table I) .
Benign breast disease
The relative risks of cases in relation to controls were determined for each of the hormonal variables for breast cancer patients, for patients with benign epithelial hyperplasia and for patients with fibrocystic disease of the breast without evidence of proliferative changes (Table II) . Because of the influence of obesity and age on oestrogen binding, all estimates of relative risk were adjusted for Quetelet's index and age and the lines of regression for each hormonal variable against Quetelet's index were plotted separately for cases and controls (Figure 4 ). Similar patterns were apparent for the cancer patients as for the patients with benign epithelial hyperplasia and those with fibrocystic disease. In each situation the cases had a higher level of free and albumin bound oestradiol at all levels of obesity compared to their controls, and conversely had lower concentrations of SHBG at all levels of obesity compared to controls. In none of these situations, however, was statistical significance reached.
Discussion
One of the problems with case-control studies is knowing if differences between patients and their controls relate to the cause of the disease or occur because of the disease process. As regards the role of oestradiol and its binding to serum proteins in the aetiology of carcinoma of the breast, we have attempted to resolve the problem by: (a) looking at differences in these hormonal variables for differing levels of risk in a control population; (b) undertaking a series of case-control studies, not only for patients with breast cancer but also for patients with histologically proven benign epithelial hyperplasia who are thus at risk of developing breast cancer, and also for a low risk group, patients with fibrocystic disease but with no proliferative changes on histology (Page et al., 1978) . If the trends seen in the breast cancer patients were also reflected in the high risk benign breast disease group, then this would be further evidence that oestradiol binding plays an aetiological role.
From the data presented in this paper, although a number of trends emerge, there is little conclusive evidence of associations between oestradiol and its binding and risk factors for breast cancer. Of all the variables of risk studied, body mass had by far the strongest association (de Moor & Joossens, 1970) and may in fact, as discussed below, be responsible for many of the trends seen with the other risk factors. We have demonstrated that women with a large body mass have a much greater proportion of their oestradiol bioavailable, i.e. free or albumin bound. Obesity itself is not a strong risk factor for breast cancer, de Waard et al. (1974) finding that only women over 65 who weighed more than 80 kg had an increased risk for breast cancer, while our own studies have shown that women who gain more than 10 kg over their reproductive years have an increased relative risk which is approximately two-fold (Ingram et al., 1989) . It should be noted that any risk, however small, if it is widely prevalent in the study population (as is obesity), can have a major impact on the incidence of the disease.
I
The association of oestradiol binding with age is interesting if one considers the relationship between breast cancer incidence and age in Western population. There is a steep rise to age 40 and thereafter the incidence plateaus until the post-menopausal years when it rises again (Fleming et al., 1981) . This fits very nicely with the changes in oestradiol binding demonstrated in Figure 1 , where the proportion of bioavailable oestradiol is high in the premenopausal years, falls over the menopausal years and is high again in later life. SHBG follws a converse pattern. One possibility is that the post-menopausal rise in free and albumin bound oestradiol (and fall in SHBG) occurs because of weight gain in these years, but adjusting for body mass index appeared to strengthen rather than reduce these associations.
The patterns of rising free and albumin bound oestradiol and falling SHBG with increase in age at menopause, and fall in SHBG with early age at menarche, support these hormonal changes as having a role in breast cancer development as early age at menarche and late age at menopause are well recognised risk factors (Pike et al., 1981) . Again, however, these changes could be accounted for by obesity as we have demonstrated in a previous study that obese women are more likely to have an early age of menarche and late age at menopause (Ingram et al., 1989) . Moore et al. (1987) similarly demonstrated that late menarche was associated with increased SHBG and adjusting for QI reduced the magnitude of the association; we have demonstrated here that adjusting for body mass reduced the assocation between age at menopause and oestradiol binding and SHBG. Little can be made of the other variables of risk and their associations with oestradiol and its binding. With the country of birth, even after taking out those who have been in Australia for more than 15 years, there were no significant differences although the numbers were small for all other than United Kingdom immigrants. Parity and age at first full term pregnancy were not significantly associated with the hormonal variables while the numbers of women in the control group with a family history of breast cancer were small and it would require a much larger study to evaluate this variable.
As regards differences in oestradiol binding between cases with breast cancer, benign epithelial hyperplasia or fibrocystic disease and their respective controls, there is a remarkably similar pattern throughout, in that after adjusting for body mass, for each group the free and albumin bound proportions of oestradiol are higher for the breast disease patients than controls, and the SHBG concentrations are correspondingly lower (Figure 4 ). This suggests that increased bioavailability of oestradiol may promote breast cancer by stimulating epithelial growth, although while the estimations of relative risk were correspondingly increased (for free and albumin-bound oestradiol) and lower (for SHBG), in no case did they reach statistical significance.
In conclusion, apart from the association between oestradiol binding and body mass, we have been unable to provide strong evidence that the degree of oestradiol binding to serum proteins is associated with risk factors for the development of breast cancer.
